This is a very narrow view. The U.K. has made sure there are international supply chains to distribute the Oxford vaccine, and far more of that is being supplied internationally than the entirety of doses exported from the EU.

I think your 50% figure is also too high, though it is a high proportion, but these doses are primarily going to wealthy countries.

If the EU were asking for U.K. doses to be routed to other (particularly poorer) countries I would be sympathetic to the position, but this spat is about getting the EU doses, not about equitable access.

And ordered 100% more than needed for the EU in order to supply other nations with that. The UK did the same so.

Except that the EU isn't getting the doses it ordered, and the shortfall is significant, and it has actually exported a significant chunk.

Whereas the UK is getting the doses it ordered, at the EU's expense, and has not actually exported any.

So.

Not exactly the same.

The U.K. is also experiencing a significant shortfall in doses compared to those that were projected to be delivered by AZ. Production yields have been lower across the board according to Oxford researchers involved in the scale up, and several delivery milestones were missed for the U.K.